Search Results - jeffrey loeb




3 Results Sort By:
Long non-protein-coding RNA molecules as therapeutics for epilepsy.
Long Non-Coding RNA Molecules as Therapeutics for Epilepsy WSU Tech#: 12-1089 Technology Summary: Long Non-coding RNA (lncRNA) were first described in 2002 from mouse, making this a relatively new technology. lncRNA transcripts far exceed the number of protein coding mRNAs in the mammalian transcriptome, but in lower copy numbers. Inventors ha...
Published: 5/19/2017   |   Inventor(s): Jeffrey Loeb, Leonard Lipovich
Keywords(s):  
Category(s): Medical, Bioinformatics, Biomedical, Biotechnology, Diagnostic, Diagnostics, Drug Discovery, Pharmaceuticals, Therapeutics
GlyB4 Fusion with Neuregulin Heparin-Targeting Domain to Block Neuregulin Signaling
We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains high affinity heparin binding to heparin and to cells that express heparan sulfates resulting in a more potent NRG antagonist. In vivo, it is targeted to peripheral nerve segments where it blocks the activity of NRG as a Sch...
Published: 5/16/2011   |   Inventor(s): Jeffrey Loeb, Qunfang Lee
Keywords(s): Anti-cancer, Biotechnology, Cancer risk, Cancer Therapies, Drug Delivery, Drug Target, Epilepsy
Category(s): Life Science, Drug Delivery, Other
Functional Improvements in Fahr Disease
Detailed Description Idiopathic cerebral calcification (a.k.a. Brain Stones) can be associated with a progressive neurological disorder for which there is no known treatment. This invention is a repurposing of an existing FDA approved compound for a new use. It relates to the treatment of Fahr?s Disease by the administration of a class of drug...
Published: 5/18/2010   |   Inventor(s): Jeffrey Loeb
Keywords(s):  
Category(s): Pharmaceuticals